An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aldeyra Therapeutics, a clinical-stage biotechnology company, will host a Research & Development Day on April 25, 2024, in New York City. The event will showcase pipeline programs and feature presentations from senior leadership.
Aldeyra Therapeutics, un'azienda biotecnologica in fase clinica, ospiterà una Giornata di Ricerca & Sviluppo il 25 aprile 2024, a New York City. L'evento presenterà i programmi in pipeline e includerà presentazioni da parte della dirigenza senior.
Aldeyra Therapeutics, una compañía biotecnológica en etapa clínica, será la anfitriona de un Día de Investigación y Desarrollo el 25 de abril de 2024, en la ciudad de Nueva York. El evento destacará los programas en desarrollo y contará con presentaciones de la alta dirección.
임상 단계의 바이오테크놀로지 회사인 알데이라 테라퓨틱스는 2024년 4월 25일 뉴욕 시티에서 연구개발 데이를 개최할 예정입니다. 이 행사에서는 파이프라인 프로그램을 소개하고 고위 리더십의 발표가 있을 예정입니다.
Aldeyra Therapeutics, une entreprise de biotechnologie en phase clinique, organisera une Journée de Recherche & Développement le 25 avril 2024, à New York City. L'événement mettra en avant les programmes de pipeline et comprendra des présentations de la haute direction.
Aldeyra Therapeutics, ein biotechnologisches Unternehmen in der klinischen Phase, wird am 25. April 2024 in New York City einen Forschungs- und Entwicklungs-Tag veranstalten. Die Veranstaltung wird die Programme der Produktpipeline vorstellen und Vorträge von der oberen Führungsebene beinhalten.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City.
Aldeyra will provide an in-depth review of pipeline programs, and the event will feature presentations from members of the Aldeyra senior leadership team.
A live audio webcast and slide presentation will be accessible from the “Investors & Media” section of the Aldeyra website at https://ir.aldeyra.com/ for 90 days following the event.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
